Indivior Pharmaceuticals (INDV) Current Leases (2021 - 2026)

Indivior Pharmaceuticals' Current Leases history runs 6 years deep, the most recent figure standing at $9.0 million for Q1 2026.

• On a quarterly basis, Current Leases fell 18.18% year-over-year to $9.0 million in Q1 2026; TTM through Mar 2026 was $9.0 million, a 18.18% decrease from a year earlier, with the FY2025 full-year figure at $10.0 million, changed 0.0% from the prior year.
• Current Leases retreated to $9.0 million in Q1 2026 per INDV's latest filing, from $10.0 million in the prior quarter.
• Across five years, Current Leases topped out at $11.0 million in Q1 2025 and bottomed at $8.0 million in Q4 2022.
• The 5-year median for Current Leases is $10.0 million (2024), against an average of $9.8 million.
• Across the five-year window, Current Leases grew 12.5% in 2023 and dropped 18.18% in 2026, its largest moves.
• Year by year, Current Leases stood at $8.0 million in 2022, then rose by 12.5% to $9.0 million in 2023, then gained by 11.11% to $10.0 million in 2024, then changed by 0.0% to $10.0 million in 2025, then fell by 10.0% to $9.0 million in 2026.
• Per Business Quant, the three latest INDV Current Leases figures stand at $9.0 million (Q1 2026), $10.0 million (Q4 2025), and $10.0 million (Q3 2025).